austedo

Drug Overview

Austedo is an advanced therapeutic medication within the field of Neurology, specifically developed for movement disorders. It belongs to a Drug Class known as Vesicular Monoamine Transporter 2 (VMAT2) inhibitors. As a highly specialized Targeted Therapy, Austedo is designed to treat the uncontrollable, dance-like movements (chorea) associated with Huntington’s disease, as well as the repetitive, involuntary movements of tardive dyskinesia.

What makes Austedo unique is its chemical design. It is considered a Smart Drug because it uses a process called deuteration. By replacing certain hydrogen atoms in the drug with a heavier isotope called deuterium, the medication breaks down more slowly in the body. This allows for smoother, more consistent medication levels in the blood, reducing side effects while maintaining strong symptom control.

• Generic Name: Deutetrabenazine
• US Brand Names: Austedo, Austedo XR (Extended-Release)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA-approved for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia in adults.
  
  Review Austedo (Deutetrabenazine) for managing Huntington’s chorea and tardive dyskinesia. Explore our comprehensive medical safety and dosage protocols.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Austedo works, it helps to look at how brain cells (neurons) communicate. Neurons send messages using chemical messengers called neurotransmitters, such as dopamine. Dopamine is heavily involved in controlling muscle movement.

Inside the neuron, a specific protein called VMAT2 acts like a packaging machine. It scoops up dopamine and packs it into tiny storage bubbles (vesicles) so it can be released to the next cell. In conditions like Huntington’s disease or tardive dyskinesia, the dopamine signaling system is overactive, leading to unwanted, jerky movements.

At the molecular level, Austedo works through the following steps:

1. VMAT2 Inhibition: Austedo binds directly to the VMAT2 protein and blocks it from working.
2. Decreased Packaging: Because VMAT2 is blocked, dopamine cannot be packaged into the storage vesicles.
3. Reduced Release: When the neuron fires, there is much less dopamine available to be released into the synapse (the gap between cells).
4. Calmer Movement Signals: With less dopamine hitting the receptors on the receiving cell, the overactive movement signals are quieted, leading to a reduction in involuntary movements.

The deuterium atoms in this Smart Drug form stronger chemical bonds than regular hydrogen. This makes it harder for liver enzymes (specifically CYP2D6) to break the drug down, providing a more stable and longer-lasting effect throughout the day.

FDA-Approved Clinical Indications

Primary Indication

• Huntington’s chorea and tardive dyskinesia: Austedo is specifically indicated to treat the involuntary, jerky, or writhing movements (chorea) caused by Huntington’s disease, and to manage tardive dyskinesia, a movement disorder often caused by long-term use of certain psychiatric medications.

Other Approved Uses

• Currently, Austedo does not have other FDA-approved indications in oncology, cardiovascular medicine, or nephrology. Its use is strictly regulated for specific neurological movement disorders.

Dosage and Administration Protocols

Austedo requires careful dose adjustment (titration) by a neurologist to find the right balance between symptom control and side effects.

Dose Adjustments and Specific Patient Populations:

• Administration: Must be taken with food to ensure proper absorption into the body. Total daily doses of 12 mg or more (of standard Austedo) must be divided and taken twice a day.
• Hepatic (Liver) Insufficiency: Austedo is contraindicated (must not be used) in patients with liver disease, as the liver cannot properly process the drug.
• CYP2D6 Poor Metabolizers: Patients taking strong CYP2D6 inhibitor medications (like fluoxetine or paroxetine), or those who genetically process these drugs slowly, should not exceed a maximum dose of 36 mg per day.

Clinical Efficacy and Research Results

Current clinical study data (updated through 2020–2026) highlights the profound impact of this Targeted Therapy on patient quality of life.

• Huntington’s Chorea (FIRST-HD Trial): Patients taking Austedo showed a significant reduction in their Total Maximal Chorea (TMC) score, dropping an average of 4.4 points from baseline (compared to a 1.9-point drop for placebo).
• Tardive Dyskinesia (AIM-TD Trial): Patients experienced a reduction in their Abnormal Involuntary Movement Scale (AIMS) score of 3.3 points, demonstrating a visibly noticeable decrease in facial and body tics.
• Long-Term Stability: Three-year open-label extension studies show that over 70% of patients maintain their reduced movement scores without needing constant dose increases, highlighting the drug’s sustained efficacy.

Safety Profile and Side Effects

Black Box Warning

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE. Austedo can increase the risk of depression and suicidal thoughts or behavior in patients with Huntington’s disease. Anyone considering the use of Austedo must balance the need for chorea treatment with the risk of depression. Close monitoring by families and caregivers is essential. (Note: This warning does not apply to patients being treated for tardive dyskinesia).

Common Side Effects (>10%)

• Somnolence (Sleepiness): The most common side effect, often occurring during the dose-increase phase.
• Dry Mouth and Diarrhea.
• Fatigue: A general feeling of tiredness or lack of energy.

Serious Adverse Events

• QTc Prolongation: A change in the electrical activity of the heart, which can lead to dangerous irregular heartbeats.
• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by high fever, stiff muscles, and confusion.
• Akathisia and Restlessness: A feeling of inner restlessness and a constant need to move.
• Parkinsonism: Experiencing stiffness, tremors, or slow movement similar to Parkinson’s disease.

Management Strategies

• Mood Monitoring: Patients, families, and caregivers must be highly vigilant for signs of worsening sadness, social withdrawal, or talk of self-harm, especially in the first few months.
• EKG Monitoring: If a patient is at risk for heart rhythm issues, a physician may order an EKG before and during treatment.

Research Areas

Huntington’s disease is a primary focus for advanced Regenerative Medicine. While Austedo is highly effective at managing symptoms, it does not cure the underlying genetic cause of the disease. Current clinical trials (2025-2026) are investigating the combination of symptom-stabilizing drugs like Austedo with experimental Cellular Therapy. In these trials, researchers transplant neural stem cells into the brain to promote Tissue Repair. By using Austedo to calm the chaotic physical movements (chorea) and stabilize the patient’s immediate condition, scientists can more accurately measure how well the new stem cells are integrating into the brain and slowing the actual progression of the disease.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Psychiatric Evaluation: A thorough screening for baseline depression or suicidal ideation.
• Liver Function Tests: To confirm that the patient’s liver is healthy enough to process the medication.
• Electrocardiogram (EKG): Recommended for patients taking other medications that affect heart rhythm.

Precautions During Treatment

• The “Food Rule”: Standard Austedo must be swallowed whole and taken with food. Austedo XR can be taken with or without food.
• Sedation Caution: Avoid driving or operating heavy machinery until you know exactly how the medication affects your alertness.
• Alcohol Avoidance: Do not drink alcohol while taking this medication, as it significantly increases severe drowsiness and the risk of depression.

“Do’s and Don’ts”

• DO take the medication exactly as prescribed, and report any mood changes to your doctor immediately.
• DO swallow the tablets whole with water.
• DON’T chew, crush, or break the tablets, as this destroys the slow-release technology.
• DON’T stop taking the medication suddenly. If treatment needs to end, your doctor will guide you on how to slowly reduce the dose.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or the use of Austedo. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide.